공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 마이크로바이옴 치료 시장

Microbiome Therapeutics

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997509
페이지 정보 영문 116 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 마이크로바이옴 치료 시장 Microbiome Therapeutics
발행일 : 2021년 04월 페이지 정보 : 영문 116 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 마이크로바이옴 치료 시장 규모는 분석기간(2020-2027년)에 58.1%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 4,600만 달러에서 2027년에는 11억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 2형 당뇨병은 분석기간 중 66.4%의 CAGR을 나타내고, 2억 4,450만 달러에 달할 전망입니다.

세계의 마이크로바이옴 치료(Microbiome Therapeutics) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • 4D pharma plc
  • AOBiome
  • Enterome SA
  • Evelo Biosciences, Inc.
  • Ferring International
  • Immuron Ltd.
  • LNC Therapeutics
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • OxThera AB
  • Rebiotix, Inc.
  • Ritter Pharmaceuticals, Inc.
  • Second Genome
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 46개사
LSH 21.04.08

Abstract:

Global Microbiome Therapeutics Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Microbiome Therapeutics estimated at US$46 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 58.1% over the analysis period 2020-2027. Type 2 Diabetes, one of the segments analyzed in the report, is projected to record a 66.4% CAGR and reach US$244.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 59% CAGR for the next 7-year period.

The U.S. Market is Estimated at $14.1 Million, While China is Forecast to Grow at 54.6% CAGR

The Microbiome Therapeutics market in the U.S. is estimated at US$14.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$172.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 53.1% and 48.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.

C. Difficile Infection Segment to Record 49.1% CAGR

In the global C. Difficile Infection segment, USA, Canada, Japan, China and Europe will drive the 49.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$13.7 Million in the year 2020 will reach a projected size of US$224.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$135.8 Million by the year 2027.

Select Competitors (Total 46 Featured) -

  • 4D pharma plc
  • AOBiome
  • Enterome SA
  • Evelo Biosciences, Inc.
  • Ferring International
  • Immuron Ltd.
  • LNC Therapeutics
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • OxThera AB
  • Rebiotix, Inc.
  • Ritter Pharmaceuticals, Inc.
  • Second Genome
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Microbiome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for C. Difficile Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for C. Difficile Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Primary Hyperoxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Primary Hyperoxyurea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 11: USA Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 12: USA 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • CANADA
    • TABLE 13: Canada Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 14: Canada 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • JAPAN
    • TABLE 15: Japan Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 16: Japan 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • CHINA
    • TABLE 17: China Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 18: China 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • EUROPE
    • TABLE 19: Europe Current & Future Analysis for Microbiome Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 20: Europe 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 21: Europe Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Europe 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • FRANCE
    • TABLE 23: France Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 24: France 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • GERMANY
    • TABLE 25: Germany Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Germany 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • ITALY
    • TABLE 27: Italy Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Italy 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 29: UK Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 30: UK 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 31: Rest of Europe Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Rest of Europe 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 33: Asia-Pacific Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 34: Asia-Pacific 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 35: Rest of World Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 36: Rest of World 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46
Back to Top
전화 문의
F A Q